Publications

5677 Results

Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314

Authors
G Dancik;D Theodorescu
Journal / Conference
European Urology Focus Mar 23;S2405-4569(22)00067-0
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID35339415
Study Number(s)
S1314

Restricted survival benefit with right-censored data

Authors
S Zhang;M LeBlanc;Y Zhao
Journal / Conference
Biometrical Journal Apr;64(4):696-713
Year
2022
Research Committee(s)
Myeloma
PMID
PMID34970772
PMC
PMC9162957
Study Number(s)
S0777

Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis

Authors
N Corsi;E Messing;A Sood;J Keeley;C Bronchema;N Rakic;M Jamil;D Dalela;S Arora;A Piontkowski;S Majdalany;M Butaney;I Rakic;P Li;M Menon;C Rogers;F Abdollah
Journal / Conference
Clinical Genitourinary Cancer Jun 25;S1558-7673(22)00140-9
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID35871040
Study Number(s)
S0337

Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia

Authors
E Watts;A Perez-Cornago;G Fensom;K Smith-Byrne;A Noor;C Andrews;M Gunter;M Holmes;R Martin;K Tsilidis;D Albanes;G Goodman;E Platz;J Schenk;Practical Consortium;N Allen;T Key;R Travis
Journal / Conference
International Journal of Cancer Oct 1;151(7):1033-1046
Year
2022
Research Committee(s)
Cancer Control
PMID
PMID35579976
PMC
PMC7613289
Study Number(s)
SWOG-9217

Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-Stage Prostate Cancer: The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance])

Authors
JK Parsons;D Zahrieh;D Patel;J Mohler;R Chen;E Paskett;H Liu;E Peil;C Rock;O Hahn;J Taylor;P Van Veldhuizen;E Small;M Morris;M Naughton;J Pierce;J Marshall
Journal / Conference
European Urology Focus Apr 30;S2405-4569(22)00061-X
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID35504836
Study Number(s)
CTSU/C70807

Checklist for Improving Patient Communication on Bladder Preservation Options: The Patient Advocate Perspective

Authors
R Bangs;D Quale;T Reed
Journal / Conference
Clinical Oncology Oct;34(10):625-629
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID34985771

Development of a measure of clinicians' self-efficacy for medical communication (SEMC)

Authors
D Feldman;M O'Rourke;B Corn;M Hudson;N Patel;R Agarwal;V Fraser;H Deininger;L Fowler;M Bakitas;R Krouse;I Subbiah
Journal / Conference
BMJ Supportive & Palliative Care, May 9;bmjspcare-2022-003593. doi: 10.1136/bmjspcare-2022-003593. Online ahead of print
Year
2022
PMID
PMID35534186

External validation of a novel computed tomography (CT)-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer (NSCLC): correlative analysis of SWOG S0819 phase III randomized trial

Authors
L Dercle;D Gomez;B Zhao;K Kelly;R Herbst;M Redman;D Gandara;L Schwartz
Journal / Conference
WCLC World Conference on Lung Cancer (August 6-9, 2022, Vienna, Austria), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S0819

Lung-MAP S1800A—Exploratory analysis of prior immunotherapy outcomes on ramucirumab plus pembrolizumab versus SOC for NSCLC with progression on prior immunotherapy

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Qian;K Minichiello;D Gandara;K Kelly;R Herbst
Journal / Conference
ESMO (September 9-13, Paris, France); Annals of Oncology (2022) 33 (suppl_7): S448-S554, poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1800A

Neoadjuvant versus adjuvant pembrolizumab for resected Stage III-IV melanoma (SWOG S1801)

Authors
S Patel;M Othus;V Prieto;M Lowe;E Buchbinder;Y Chen;J Hyngstrom;C Lao;T Truong;S Chandra;K Kendra;C Devoe;A Hedge;A Mangla;E Sharon;L Korde;J Moon;V Sondak;A Ribas
Journal / Conference
ESMO (September 9-13, 2022 Paris, France), oral Presidential Symposium; Annals of Oncology (2022) 33 (suppl_7): S808-S869
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
S1801